TC Biopharm (Holdings) (TCBPY) AI Stock Analysis

• Market Cap: $3.51K
• Dividend Yield: N/A
• Average Volume (3M): 8.91K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.12
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,103,054
• 10 Day Avg. Volume: 7,787
• 30 Day Avg. Volume: 8,914
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: ― N/A
• Price Target: ―
• Action: N/A Date: ―
• Date: Action: N/A ―

Positive Factors

Innovative Product Pipeline

TC Biopharm's focus on gamma-delta T cell technology positions it at the forefront of innovative cancer treatments, offering potential long-term growth through successful product development and commercialization.

Negative Factors

Declining Revenues

A significant decline in revenue indicates challenges in product commercialization and market penetration, posing risks to long-term financial viability and growth prospects.

TC Biopharm (Holdings) Business Overview & Revenue Model

Company Description

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in t...

Read more

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in t...

How the Company Makes Money

TC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develo...

Read more

TC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develo...

TC Biopharm (Holdings) Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

TC Biopharm (Holdings) Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCBPY, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.06, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 36.06 is Neutral, neither overbought nor oversold. The STOCH value of 5.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCBPY.

TC Biopharm (Holdings) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TCBPY	―	$3.51K	―	―	―	―	―
SCNI	44 Neutral	$2.56M	-0.20	―	―	99.48%	-474.47%
DRMA	44 Neutral	$4.99M	-0.28	-203.36%	―	―	93.60%

TC Biopharm (Holdings) Corporate Events